HealthDay on MSN

Early Use of Higher-Efficacy Therapies Recommended for Moderate-to-Severe Crohn Disease

Early use of higher-efficacy therapies is recommended for patients with moderately to severely active Crohn disease (CD), ...
Taiwan News

Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the ...

ZYMFENTRA ® is a prescription medicine indicated in adults for maintenance treatment of: Moderately-to-severely active Crohn's disease following treatment with an infliximab product administered ...
Medical Dialogues

Real-World Evidence in Psoriatic Arthritis: PRO-SPIRIT Study - Video

In the video, Dr. Nicola J. Gullick, a Consultant Rheumatologist in Coventry and one of the investigators on the PRO-SPIRIT ...

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...